FARMINGDALE, N.Y., Jan. 24 /PRNewswire-FirstCall/ -- Misonix, Inc. , a developer of ultrasonic medical device technology for the treatment of cancer and other health conditions, announced today that it has been invited to present at the Roth Capital Partners 18th Annual Growth Stock Conference. The conference is being held from February 20-22, 2006, at the St. Regis Monarch Beach Resort & Spa in Dana Point, California.
Misonix management will present on Wednesday, February 22nd, at 9:00 AM Pacific time. The event is recognized as one of the nation’s largest institutional investor conferences for small and micro cap companies and will feature presentations from nearly 300 companies with an average market capitalization of approximately $350 million. Presenting companies were selected by Roth Capital’s equity research team and other executives and are representative of the healthcare, technology, consumer, and financial services sectors.
Roth Capital Partners, LLC (“Roth”) has been a leader and innovator in the small and micro cap markets since 1984. Roth provides the full spectrum of investment banking services, including raising capital, research coverage, creating liquidity, trading and market making, merger and acquisition advisory services, sales support, and investor conferences, to its customers. For more information, please visit www.rothcapital.com.
Misonix develops, manufactures, and markets medical, scientific, and industrial ultrasonic and air pollution systems. The Company has been at the forefront of ultrasonic technology for over 50 years. Misonix’s ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound (“HIFU”) technology to destroy deep-seated cancerous tissues without effecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of $3 billion annually, Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. In particular, the Company may not be successful in its efforts with respect to strategic opportunities for its Laboratory and Scientific Division and the affect this activity may have on the other businesses within the Company. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, uncertainties as a result of research and development, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K.
Misonix Contact: Investor Relations Contact: Richard Zaremba Jordan M. Darrow Chief Financial Officer Darrow Associates, Inc. 631-694-9555 631-367-1866 invest@misonix.comjdarrow@optonline.net
Misonix, Inc.
CONTACT: Richard Zaremba, Chief Financial Officer of Misonix, Inc.,+1-631-694-9555, or invest@misonix.com; or investors, Jordan M. Darrow ofDarrow Associates, Inc., +1-631-367-1866, or jdarrow@optonline.net
Web site: http://www.misonix.com/